NCT01816048

NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis

A Pharmacodynamic Study Using NaF PET/CT Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Metastatic Castrate Resistant Prostate Cancer to Bone

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: University of Wisconsin, Madison · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess whether NaF PET/CT scans can be used to evaluate treatment response in bone metastases in subjects with prostate cancer treated with the investigational drug, TAK-700.

Conditions

• Prostatic Neoplasms
• Prostate Cancer

Interventions

Type	Name	Description
DRUG	TAK-700	TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
RADIATION	Fluorine F 18 Sodium Fluoride	Undergo NaF F18 PET/CT scan
PROCEDURE	Positron Emission Tomography	Undergo 18F NaF PET/CT scan
PROCEDURE	Computed Tomography	Undergo 18F NaF PET/CT scan

Timeline

• Start date: 2013-05-01
• Primary completion: 2015-12-01
• Completion: 2016-11-01
• First posted: 2013-03-21
• Last updated: 2019-12-09
• Results posted: 2017-07-19

Locations

1 site across 1 country: United States